Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS)

Oral Diseases

Volumn 15, Issue 1, 2009, Pages 52-60

  Navazesh, M ^a   Mulligan, R ^h   Karim, R ^h   Mack, W J ^h   Ram, S ^h   Seirawan, H ^h   Greenspan, J ^h   Greenspan, D ^h   Phelan, J ^h   Alves, M ^h   Phelan, Joan ^b   Vernillo, Anthony ^b   LaMarre, Manley ^b   Greenspan, Deborah ^c   Greenspan, John S ^c   Macphail, Laurie A ^c   Mulligan, Roseann ^d   Navazesh, Mahvash ^d   Galligan, Joyce ^d   Arevalo, Lupe ^d   Mack, Wendy ^d   Karim, Roksana ^d   Ram, Saravanan ^d   Seirawan, Hazem ^d   Bautista King, Sharon ^d   Vargas, Claudia ^d   Alves, Mario ^e   Gange, Stephen J ^f   Barron, Yolanda ^f   Redford, Maryann ^g   more..

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^h NONE

Author keywords

Antiretroviral therapy; HAART; HIV; PI based HAART; Salivary gland enlargement; Salivary gland function

Indexed keywords

ABACAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; RISK FACTOR; SALIVARY GLAND; SALIVARY GLAND FUNCTION; SALIVATION; SIDE EFFECT; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV SEROPOSITIVITY; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RNA, VIRAL; SALIVA; SALIVARY GLANDS; SECRETORY RATE; SIALADENITIS; XEROSTOMIA; YOUNG ADULT;

EID: 57549086618     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2008.01456.x     Document Type: Article

References (51)

1. Aguirre-Urizar JM, Echebarria-Goicouria MA, Eguia-del-Valle A (2004). Acquired immunodeficiency syndrome: manifestations in the oral cavity. Med Oral Patol Oral Cir Bucal 9 (Suppl 153 157 148 153.
2. Barkan SE, Melnick SL, Preston-Martin S et al (1998). The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 9 : 117 125.
3. Basu D, Williams FM, Ahn CW, Reveille JD (2006). Changing spectrum of the diffuse infiltrative lymphocytosis syndrome. Arthritis Rheum 55 : 466 472.
4. Bruner JM, Cleary KR, Smith FB, Batsakis JG (1989). Immunocytochemical identification of HIV (p24) antigen in parotid lymphoid lesions. J Laryngol Otol 103 : 1063 1066.
5. Carr A, Samaras K, Burton S, et al (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids 12 : F51 58.
6. Ceballos-Salobrena A, Gaitan-Cepeda LA, Ceballos-Garcia L, Lezama-Del Valle D (2000). Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS 14 : 627 635.
7. Chambon P (1996). A decade of molecular biology of retinoic acid receptors. FASEB J 10 : 940 954.
8. Dawes C (1987). Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 66 : 648 653.
9. Greenspan J, Greenspan D (2002). The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis 8 (Suppl. 2 34 39.
10. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS (2001). Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 357 : 1411 1412.
11. Ioachim HL, Ryan JR, Blaugrund SM (1988). Salivary gland lymph nodes. The site of lymphadenopathies and lymphomas associated with human immunodeficiency virus infection. Arch Pathol Lab Med 112 : 1224 1228.
12. Itescu S, Brancato LJ, Buxbaum J et al (1990). A diffuse infiltrative CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection: a host immune response associated with HLA-DR5. Ann Intern Med 112 : 3 10.
13. Kozinetz CA, Carter AB, Simon C et al (2000). Oral manifestations of pediatric vertical HIV infection. AIDS Patient Care STDs 14 : 89 94.
14. Kravcik S (2000). HIV lipodystrophy: a review. HIV Clin Trials 1 : 37 50.
15. Laskaris G, Hadjivassiliou M, Stratigos J (1992). Oral signs and symptoms in 160 Greek HIV-infected patients. J Oral Pathol Med 21 : 120 123.
16. Levine AM, Karim R, Mack W et al (2006). Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. Arch Intern Med 166 : 405 410.
17. Li E, Norris AW (1996). Structure/function of cytoplasmic vitamin A-binding proteins. Annu Rev Nutr 16 : 205 234.
18. Lin AL, Johnson DA, Stephan KT, Yeh CK (2003). Alteration in salivary function in early HIV infection. J Dent Res 82 : 719 724.
19. Lin AL, Johnson DA, Stephan KT, Yeh CK (2004). Salivary secretory leukocyte protease inhibitor increases in HIV infection. J Oral Pathol Med 33 : 410 416.
20. Lin AL, Johnson DA, Sims CA, Stephan KT, Yeh CK (2006). Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 : 318 324.
21. Mandel L, Hong J (1999). HIV-associated parotid lymphoepithelial cysts. J Am Dent Assoc 130 : 528 532.
22. Mandel L, Surattanont F (2002). Regression of HIV parotid swellings after antiviral therapy: case reports with computed tomographic scan evidence. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94 : 454 459.
23. Mulligan R, Phelan JA, Brunelle J et al (2004). Baseline characteristics of participants in the oral health component of the Women's Interagency HIV Study. Community Dent Oral Epidemiol 32 : 86 98.
24. Navazesh M, Mulligan R, Komaroff E, Redford M, Greenspan D, Phelan J (2000). The prevalence of xerostomia and salivary gland hypofunction in a cohort of HIV-positive and at-risk women. J Dent Res 79 : 1502 1507.
25. Navazesh M, Denny P, Sobel S (2002). Saliva: a fountain of opportunity. J Calif Dent Assoc 30 : 783 788.
26. Navazesh M, Mulligan R, Barron Y et al (2003). A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 : 693 698.
27. Nicolatou-Galitis O, Velegraki A, Paikos S et al (2004). Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis 10 : 145 150.
28. Olive A, Salavert A, Manriquez M, Clotet B, Moragas A (1998). Parotid lipomatosis in HIV positive patients: a new clinical disorder associated with protease inhibitors. Ann Rheum Dis 57 : 749.
29. Panayiotakopoulos GD, Aroni K, Kyriaki D et al (2003). Paucity of Sjogren-like syndrome in a cohort of HIV-1-positive patients in the HAART era. Part II. Rheumatology (Oxford) 42 : 1164 1167.
30. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. (2000). Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89 : 299 304.
31. Patton LL, Phelan JA, Ramos-Gomez FJ, Nittayananta W, Shiboski CH, Mbuguye TL (2002). Prevalence and classification of HIV-associated oral lesions. Oral Dis 8 (Suppl. 2 98 109.
32. Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, Gonzalez-Ramirez I, Ponce-de-Leon S (2003). The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico. Medicine (Baltimore) 82 : 39 50.
33. Ramos-Gomez FJ, Flaitz C, Catapano P, Murray P, Milnes AR, Dorenbaum A (1999). Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected pediatric patients. Collaborative Workgroup on Oral Manifestations of Pediatric HIV Infection. J Clin Pediatr Dent 23 : 85 96.
34. Reichart PA (2003). Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma. Med Microbiol Immunol 192 : 165 169.
35. Reichart P (2006). US1 HIV - changing patterns in HAART era, patients' quality of life and occupational risks. Oral Dis 12 (Suppl. 1 3.
36. Rohlmann A, Gotthardt M, Hammer RE, Herz J (1998). Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 101 : 689 695.
37. Schiodt M (1997). Less common oral lesions associated with HIV infection: prevalence and classification. Oral Dis 3 (Suppl. 1 S208 S213.
38. Schiodt M, Greenspan D, Daniels TE et al (1989). Parotid gland enlargement and xerostomia associated with labial sialadenitis in HIV-infected patients. J Autoimmun 2 : 415 425.
39. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA (2000). Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 29 : 336 341.
40. Scully C, Diz Dios P (2001). Orofacial effects of antiretroviral therapies. Oral Dis 7 : 205 210.
41. Ship JA, Fox PC, Baum BJ (1991). How much saliva is enough? 'Normal' function defined J Am Dent Assoc 122 : 63 69.
42. Silverberg MJ, Gore ME, French AL et al (2004). Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis 39 : 717 724.
43. Soberman N, Leonidas JC, Berdon WE et al (1991). Parotid enlargement in children seropositive for human immunodeficiency virus: imaging findings. AJR Am J Roentgenol 157 : 553 556.
44. Stevens GJ, Grecko R (1999). Preclinical investigations into the mechanism by which HIV protease inhibitors may induce metabolic disorders [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
45. Tontonoz P, Hu E, Spiegelman BM (1995). Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 5 : 571 576.
46. Uccini S, D'Offizi G, Angelici A et al (2000). Cystic lymphoepithelial lesions of the parotid gland in HIV-1 infection. AIDS Patient Care STDs 14 : 143 147.
47. US Department of Health and Human Services (2002). Henry J. Kaiser Family Foundation. Guidelines for the use of Antiretroviral Agents in HIVinfected Adults and Adolescents. HIV/AIDS Treatment Information Service : Rockville, MD : Available at: http://aidsinfo.nih.gov/guidelines [accessed on 20 February 2008].
48. Vargas PA, Mauad T, Bohm GM, Saldiva PH, Almeida OP (2003). Parotid gland involvement in advanced AIDS. Oral Dis 9 : 55 61.
49. Vicandi B, Jimenez-Heffernan JA, Lopez-Ferrer P et al (1999). HIV-1 (p24)-positive multinucleated giant cells in HIV-associated lymphoepithelial lesion of the parotid gland. A report of two cases. Acta Cytol 43 : 247 251.
50. Yeh CK, Fox PC, Ship JA et al (1988). Oral defense mechanisms are impaired early in HIV-1 infected patients. J Acquir Immune Defic Syndr 1 : 361 366.
51. Yeni PG, Hammer SM, Carpenter CC et al (2002). Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288 : 222 235.